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Placebo by proxy
Clinicians’ and family members’ feelings and perceptions about a treatment may influence their
judgments about its effectiveness
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The effect of placebo on the patient and the patient’s
environment is often debated, but people other than the patient
may also feel better when a patient receives placebo treatment.
The anthropologist Claude Lévi-Strauss alluded to this when
he described how medical treatments, including those where
ritual alone provides the cure, occur in a social context and
convey a “sense of security” to the social group.
1
Cliniciansandfamilymembersmayhaveanemotionalresponse
to a patient’s treatment and think that the treatment is helping
the patient even in the absence of any direct physiological
benefit to the patient or indication from the patient that the
treatment is working. These feelings and perceptions may arise
when placebos, including “impure” placebos, such as active
drugs or operations that have no effect on the disease process,
areusedinclinicalpracticeandresearchsettings.Becausethese
feelings and perceptions are not accounted for in descriptions
oftheplaceboeffectandcanexistindependentlyofanyplacebo
effect on the patient, they can be described as placebo effects
by proxy, or placebo by proxy for short. Although placebo by
proxy has important implications, the phenomenon is
underappreciated and rarely discussed.
Placebo by proxy could be as ubiquitous as the placebo effect,
and in some situations placebo by proxy can dominate clinical
decisionmaking.Forexample,theparentsofachildwithaviral
upper respiratory illness may believe that the child needs
antibiotics,andparentalexpectationsorthedoctor’sperception
of parental expectations (or both) may influence prescribing
patterns.
2 3 Antibiotics are overprescribed in these situations
and function as impure placebos
4; the psychological benefit to
the parent, such as a relief from worry, represents placebo by
proxy.
In the absence of evidence to support long term use of
antipsychotics in patients with dementia and a history of
agitation,aggression,orpsychosis,
5 6placebobyproxymayhelp
to explain why clinicians often maintain their patients on these
drugs. In a controlled double blind study of discontinuation of
psychotropics in a sample of patients with dementia who were
takingthesedrugsbecauseofahistoryofagitation(67.3%were
taking antipsychotics), the authors found a lack of an effect of
psychotropics when they compared mean scores on behaviour
rating scales during the treatment and placebo phases of the
trial.
6 However, clinical workers were resistant to stopping
treatment because they had “a great deal of faith in the utility
of these drugs to control agitation in this population.”
6
Psychotropics functioned as impure placebos for many of these
patients, and the concern of clinicians that patients would
decompensate without these drugs provides another example
of placebo by proxy.
In addition to influencing clinical decision making, placebo by
proxycouldinfluenceestimationsoftreatmentoutcomeintrials,
especiallywhentheperceptionsofcliniciansorfamilymembers




on the opinions of parents, teachers, or clinicians (or a
combination thereof).
8 Ten randomised controlled trials and a
meta-analysis showed robust and consistent reductions in core
symptoms of autism as measured by standardised rating scales
in both the treatment and placebo groups, but no significant
differences were seen between the groups on these measures.
8 9
The robust response to placebo may have been influenced by
david_grelotti@hms.harvard.edu
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d4345 doi: 10.1136/bmj.d4345 (Published 11 August 2011) Page 1 of 2
Editorials
EDITORIALSanecdotalreports,whichgeneratedpositivepressaboutsecretin
and gave rise to the need for clinical trials.
8 9 Perception or
misperception by parents may also partially explain a larger
placebo response in children than in adults participating in






confidence interval 1.69 to 2.01), compared with 0.67 (0.49 to
0.85) for patient reported improvement.
11 For irritable bowel
syndrome, the pooled placebo response rate for physician rated
improvement is 53.0%, compared with 37.4% for patient rated
improvement (P=0.005).
12
The different mechanisms that underlie the placebo effect are
likely to shape placebo by proxy also.
12 These processes may
include seeing other patients respond to the same drug,
associative learning such as conditioning, a supportive
physician-patient relationship, and reduced anxiety.
Placebo by proxy and the placebo effect may interact to create
positivechange.Forexample,ifcliniciansandfamilymembers
feel empowered and optimistic about a disease, the patient’s
environment can become less stressful and more supportive.
Cliniciansandfamilymembersmayreacttoplacebobysmiling
more,payingmoreattentiontothepatient,promotingtreatment
adherence, encouraging the patient to engage in new activities,
or creating other targets for behavioural change.
8 9 In this way,
placebo by proxy may elicit changes in the patient’s
psychosocial context that mediate the placebo effect.
Although placebo by proxy may enhance clinical outcomes, it
mightalsocauseharm.Iftreatmentrelateddecisionsareunduly
weighted towards providing a psychological benefit to people
other than the patient, the patient may not benefit from the
treatmentyetmaystillbeartherisks.Thetreatmentsmentioned
abovecostmoneyandarenotbenign:antibioticscausediarrhoea
and are associated with antibiotic resistance, antipsychotics are
associated with an increased risk of death in elderly patients
with dementia related psychosis, and secretin infusion may
result in a life threatening allergic reaction. Placebo by proxy
may create a false sense that a patient is getting better and
therebypreventmoreappropriatetreatment,
7 8oritmayproduce
changes in attitude and behaviour towards the patient that lead
to neglect. Placebo by proxy is probably more likely to cause
harm when decisions are made in the absence of clinical
evidence and when patients cannot make decisions for
themselves.
Treatment benefits could be maximised and harms mitigated if
placebobyproxyweretakenintoaccountwhenmakingclinical
decisions. For many of the above clinical situations, an
appreciation of placebo by proxy may prompt clinicians to
question attachments to treatment practices that are not
supported by evidence. Placebo by proxy could be used as a
potential clinical tool. For example, it may be possible to boost
the psychological benefit of a patient’s treatment by generating
appropriate enthusiasm for treatment among those involved in
the patient’s care. Because almost every treatment related
decision is shared and patients sometimes agree to treatment to
make their clinicians and family members happy, clinicians
should be aware of placebo by proxy when guiding clinical
decisions and evaluating treatment response.
Competing interests: All authors have completed the Unified Competing
Interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare: TJK was supported by
grant K24 AT004095 from the NIH-NCCAM; DJG has received
unrestricted research funding from the American Psychiatric Institute
for Research and Education sponsored by Janssen Pharmaceuticals
in the previous three years; DJG is a resident member of the Autism
and Intellectual Disabilities Committee of the American Academy of
Child and Adolescent Psychiatry.
Provenance and peer review: Not commissioned; externally peer
reviewed.
1 Lévi-Strauss C. Structural anthropology. Jacobson C, Schoepf BG, translators. Basic
Books, 1963.
2 Bauchner H, Pelton SI, Klein JO. Parents, physicians, and antibiotic use. Pediatrics
1999;103:395-401.
3 Mangione-Smith R, McGlynn EA, Elliott MN, Krogstad P, Brook RH. The relationship
between perceived parental expectations and pediatrician antimicrobial prescribing
behavior. Pediatrics 1999;103:711-8.
4 Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with
colds, upper respiratory tract infections, and bronchitis [published correction in JAMA
1998;279:1702]. JAMA 1998;279:875-7.
5 Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al; CATIE-AD
Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s
disease. N Engl J Med 2006;355:1525-38.
6 Cohen-Mansfield J, Lipson S, Werner P, Billig N, Taylor L, Woosley R. Withdrawal of
haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind
study. Arch Intern Med 1999;159:1733-40.
7 Grelotti DJ. Book review of clinical manual for the treatment of autism: Hollander E,
Anagnostou E, eds. J Am Acad Child Adolesc Psychiatry 2008;47:1354-5.
8 Sandler A. Placebo effects in developmental disabilities: implications for research and
practice. Ment Retard Dev Disabil Res Rev 2005;11:164-70.
9 Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder.
Cochrane Database Syst Rev 2005;3:CD003495.
10 Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children
than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy.
PLoS Med 2008;5:e166.
11 Rief W, Nestoriuc Y, Weiss S, Weizel E, Barsky AJ, Hofmann SG. Meta-analysis of the
placebo response in antidepressant trials. J Affect Disord 2009;32:1041-56.
12 Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable
bowel syndrome. Aliment Pharmacol Ther 2010;32:144-58.
Cite this as: BMJ 2011;343:d4345
© BMJ Publishing Group Ltd 2011
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d4345 doi: 10.1136/bmj.d4345 (Published 11 August 2011) Page 2 of 2
EDITORIALS